ESMO 2019, Barcelona Day 1 Highlights

Prof. Fred Saad (University of Montreal Hospital Centre, Université de Montréal, Quebec, Canada) joins touchONCOLOGY to discuss clinical trial highlights in prostate cancer presented at EMSO 2022. He highlights the results from one of the phase 3 STAMPEDE trials, investigating combination abiraterone and enzalutamide or abiraterone and prednisolone, for metastatic hormone sensitive prostate cancer (mHSPC), […]

In the PROpel trial, abiraterone and olaparib significantly prolonged radiographic progression free survival in patients with metastatic castration-resistant prostate cancer. Prof. Fred Saad (University of Montreal Hospital Centre, Université de Montréal, Quebec, Canada) joins touchONCOLOGY to discuss the biomarker analysis from the primary analysis, and updated overall survival and safety data. The abstract entitled ‘Biomarker […]

ASCO 2022 showcased many important studies in prostate cancer. Prof. Axel Merseburger (Department of Urology, University of Lubeck, Germany), touchONCOLOGY’s Editor-in-Chief, joins us to share his highlights. In this interview he discusses: the phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy in patients with prostate cancer (0:40); the interim overall […]